glatiramer

glatiramer

 [glah-tir´ah-mer]
an immunomodulator used as the acetate ester to reduce relapses in multiple sclerosis; administered by subcutaneous injection.

glatiramer

/gla·tir·a·mer/ (glah-tir´ah-mer) an immunomodulator used as the acetate ester to reduce relapses in multiple sclerosis.

glatiramer

a multiple sclerosis drug.
indication It is used to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
contraindications Known hypersensitivity to this drug or to mannitol prohibits its use.
adverse effects Adverse effects include migraine, palpitations, syncope, tachycardia, vasodilation, nausea, vomiting, diarrhea, anorexia, gastroenteritis, ecchymosis, lymphadenopathy, edema, weight gain, arthralgia, anxiety, hypertonia, tremor, vertigo, speech disorder, agitation, confusion, bronchitis, dyspnea, pruritus, rash, sweating, urticaria, erythema, ear pain, urinary urgency, dysmenorrhea, and vaginal moniliasis.

glatiramer

A mixture of synthetic polypeptides that act on the immune system and are claimed to reduce substantially the frequency of relapses in people with relapsing MULTIPLE SCLEROSIS. Its use is restricted to those who have suffered a relapse in the previous two years. The drug is unsuitable for patients who are severely affected and unable to get about unaided. A brand name is Copaxone.
References in periodicals archive ?
The FAS Russia Commission considered the complaint of ZAO Biocad against the actions of the Ministry of Health of the Russian Federation when purchasing the Glatiramer acetate drug used for the treatment of multiple sclerosis with a contract price of about 650 million rubles.
The Food and Drug Administration approved Mylan's Abbreviated New Drug Applications (ANDAs) for glatiramer acetate injection 40 mg/ml for three-times-a-week injection, a substitutable generic version of Teva's Copaxone 40 mg/ml, and glatiramer acetate injection 20 mg/ml for once-daily injection, a substitutable generic version of Teva's Copaxone 20 mg/ml.
Glatopa[TM], a generic form of glatiramer acetate injection that was initially available only under Teva's registered trademark Copaxone[R], is now available from Sandoz, the generic pharmaceuticals division of Novartis.
1] Other drugs precipitating Nicolau syndrome include penicillins, non-steroidal anti-inflammatory drugs like piroxicam and diclofenac, local anesthetics like lidocaine, antipsychotics, antiepileptics and glatiramer acetate.
BANKING AND CREDIT NEWS-May 28, 2014-Mapi Pharma receives extension for Glatiramer Acetate Depot
On quality of life measures, monotherapy and combination therapy proved largely equal--and equally well tolerated--in the "CombiRx" study, in which half of the patients got the combination and a quarter got either glatiramer acetate (Copaxone) or interferon beta-la (Avonex) alone plus a placebo.
SAN DIEGO -- Glatiramer acetate and interferon beta-la used in combination were no more effective for patients with relapsing-remitting multiple sclerosis than were either agent alone in a 3-year, randomized trial.
Ilk basamak tedavi secenegi olan interferonlarin (interferon-beta1a, interferon-beta-1b) ve glatiramer asetatin (GA, Copolymer 1) olusturdugu bu grup tedavilerin atak sikligi ve hastalik progresyonu uzerine olumlu etkisi bulunmaktadir (2,5).
The drug can be given to patients whose condition is not being controlled by self-administered injections of beta interferon or glatiramer acetate.
Khoury, of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues assessed the effects of albuterol treatment as an add-on therapy for patients starting treatment with glatiramer acetate, currently approved as a therapy for relapsing-remitting MS.
Glatiramer acetate significantly delayed the conversion of clinically isolated syndrome to clinically definite multiple sclerosis, according to a randomized, double-blind, placebo-controlled trial published in the Lancet.
New data demonstrating remyelination of damaged axons in mice treated with glatiramer acetate (COPAXONE") were published in the October 6, 2009, Proceedings of the National Academy of Sciences.